Skip to main content
. 2016 Aug 18;115(7):776–783. doi: 10.1038/bjc.2016.249

Table 5. Hazard ratios associated with a positive vs a negative BRCA2 mutation status, overall and according to ER status, and for women in different treatment categories (period of diagnosis 1980–2012).

  HR 95% CI P-value
BRCA2 1.85a 1.35–2.52 <0.001
BRCA2 (multivariate) 1.61b 1.11–2.35 0.01
ER status      
Positive 1.92b 1.20–3.05 0.006
Negative 1.12b 0.54–2.31 0.77
Surgery      
Lumpectomy 4.16b 1.88–9.17 <0.001
Mastectomy 1.25b 0.82–1.93 0.3
Adjuvant chemotherapy      
None 2.38b 1.31–4.34 0.005
Any 1.21b 0.74–2.00 0.45
Anthracycline 1.31b 0.58–2.95 0.52
Non-anthracycline 1.19b 0.61–2.27 0.62
Radiation      
None 1.18b 0.68–2.06 0.55
Any 2.07b 1.23–3.50 0.006
Adjuvant hormone therapy      
None 1.37b 0.85–2.21 0.2
Any 3.13b 1.53–6.41 0.002

Abbreviations: ER=oestrogen receptor; HR=hazard ratio.

a

Adjusted for year of birth and year of diagnosis.

b

Adjusted for year of birth, year of diagnosis, size, nodal status, grade, ER status and all other treatment categories.